新股消息 | 博纳西亚递表港交所 专注于临床CRO试验技术服务

Company Overview - BonaSia (Hangzhou) Pharmaceutical Technology Co., Ltd. is a clinical contract research organization (CRO) based in Hangzhou, China, focusing on digital empowerment in innovative drug clinical research [4] - The core business includes providing clinical trial technical services to domestic and international pharmaceutical and biotechnology companies, aiming to accelerate the R&D and commercialization of chemical drugs and biological products [4] - The company integrates digital systems into the clinical research process, enhancing efficiency and reducing R&D costs through data-driven strategies and automated workflows [4] Financial Performance - For the fiscal year 2023, the company reported revenues of approximately RMB 370.5 million, with a gross profit of about RMB 124.29 million, resulting in a gross margin of 33.5% [6][7][9] - The projected revenues for 2024 and the first nine months of 2024 are RMB 340.25 million and RMB 236.69 million, respectively, with expected profits of RMB 67.29 million and RMB 44.56 million for the same periods [7][8] - The company has maintained a consistent gross margin, with figures of 38.3% for 2024 and 37.8% for the first nine months of 2024 and 2025 [9] Industry Overview - The global CRO services market is primarily divided into drug discovery services, preclinical CRO services, and clinical CRO services, with clinical CRO services accounting for approximately 70% of the market [10] - The global clinical CRO services market is projected to reach USD 59.2 billion in 2024, with an expected growth to USD 131.4 billion by 2034, reflecting a compound annual growth rate (CAGR) of 8.3% from 2024 to 2034 [10][15] - In China, the clinical CRO services market is expected to grow from RMB 46.1 billion in 2024 to RMB 148.7 billion by 2034, with a CAGR of 12.4% during the same period, indicating a faster growth rate compared to the global market [12][15]